D-VRD induction and autologous transplant in patients ≥70 years - Scorecard - MDSpire

D-VRD induction and autologous transplant in patients ≥70 years

  • By

  • Oren Pasvolsky

  • Curtis Marcoux

  • Denái R. Milton

  • Mark R. Tanner

  • Muhammad Bilal Islam

  • Qaiser Bashir

  • Samer Srour

  • Neeraj Saini

  • Paul Lin

  • Jeremy Ramdial

  • Yago Nieto

  • Guilin Tang

  • Yosra Aljawai

  • Asad A. Haider

  • Hans C. Lee

  • Krina K. Patel

  • Partow Kebriaei

  • Sheeba K. Thomas

  • Robert Z. Orlowski

  • Richard E. Champlin

  • Elizabeth J. Shpall

  • Muzaffar H. Qazilbash

  • June 5, 2026

  • 0 min

Share

Clinical Scorecard: Induction with D-VRD and Autologous Hematopoietic Cell Transplantation in Patients Aged 70 and Older

At a Glance

CategoryDetail
ConditionMultiple Myeloma (MM)
Key MechanismsDaratumumab, bortezomib, lenalidomide, and dexamethasone (D-VRD) induction followed by autologous hematopoietic cell transplantation (autoHCT)
Target PopulationPatients aged 70 years and older with newly diagnosed MM
Care SettingThe University of Texas MD Anderson Cancer Center

Key Highlights

  • D-VRD induction followed by autoHCT shows comparable outcomes in older patients vs younger patients.
  • No non-relapse mortality events reported in either age group.
  • Similar pre- and post-transplant response rates between older and younger patients.
  • Median progression-free survival (PFS) was 36.5 months in older patients.
  • One- and two-year overall survival (OS) rates were 100% and 92% in older patients.

Guideline-Based Recommendations

Diagnosis

  • Evaluate newly diagnosed MM patients for eligibility for D-VRD induction.

Management

  • Consider D-VRD induction followed by autoHCT for patients aged ≥70 years.

Monitoring & Follow-up

  • Assess measurable residual disease (MRD) pre- and post-autoHCT.

Risks

  • Monitor for potential second primary malignancies, particularly in younger cohorts.

Patient & Prescribing Data

125 patients, with 27 (22%) aged ≥70 years and 98 (78%) aged <70 years.

Older patients received lower doses of lenalidomide and more commonly underwent conditioning with melphalan alone.

Clinical Best Practices

  • Utilize inverse probability weighting to adjust for confounders in outcome analysis.
  • Ensure comprehensive monitoring of engraftment and MRD status post-transplant.

Related Resources & Content

Original Source(s)

D-VRD induction and autologous transplant in patients ≥70 years

  • by Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Mark R. Tanner, Muhammad Bilal Islam, Qaiser Bashir, Samer Srour, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Asad A. Haider, Hans C. Lee, Krina K. Patel, Partow Kebriaei, Sheeba K. Thomas, Robert Z. Orlowski, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash

  • June 5, 2026

Related Content

Rearming mesenchymal stem cells with engineering strategies to combat cancer

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma